Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences/ProThera Biologics

Drug Profile

Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences/ProThera Biologics

Latest Information Update: 19 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ProMetic Life Sciences; ProThera Biologics
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 19 Nov 2015 ProMetics and ProThera agree to co-promote and co-develop plasma-derived inter-alpha inhibitor proteins in Canada for Inflammation
  • 19 Nov 2015 Early research in Inflammation in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top